Pulmonx Corporation (LUNG) Fair Value 2026

LUNG · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.2 /10

32 fundamental signals · 2 models active

Value Trap Risk

SAFE (19/100)

Quick Summary — As of 2026-08-27, Pulmonx Corporation (LUNG) trades at $2.42, versus a $1.64 median fair value across its 2 active models — 32.3% below the current price. QOC: 7.2/10. Value Trap Risk: 19/100 (SAFE). 2/13 models active.

Key Facts

Ticker
LUNG
Price
$2.42
Quality Score
7.2/10
Value Trap Risk
19/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Pulmonx Corporation (LUNG) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Pulmonx Corporation (LUNG) appears overvalued as of : the median of 2 independent fair value estimates is $1.64, 32.3% below the current price of $2.42. Estimates range from $1.49 to $1.79. LUNG scores 7.2/10 on fundamental quality and 19/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. LUNG’s -32.3% gap is wider than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Pulmonx Corporation Stock in 2026? →

What Fair Value Does Each Model Give LUNG?

2 Intrinsic Value Models vs. Current Price ($2.42)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $1.49 -38.4%
Option-Based · Medium Conviction
 $1.79 -26.2%

All Models Active

All 2 models are displayed above.

What Is Pulmonx Corporation (LUNG) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Pulmonx Corporation's intrinsic value is estimated at $1.64. Trading at its current price of $2.42, the valuation engine raises significant caution: 2 of 2 models flag downside risk, projecting a median implied return of -32.3%.

What Do the Models Say About LUNG?

2 of 13 models are currently active for LUNG. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for LUNG is $1.64 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does LUNG Rank in Medical Devices?

Among 157 Medical Devices stocks, LUNG ranks #41 by Quality of Company score. CirclFi's QOC score of 7.2/10 evaluates 32 fundamental signals. A score of 7.2 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to healthcare company businesses. For Pulmonx Corporation, metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is LUNG a Value Trap?

CirclFi's Value Trap algorithm assigns LUNG a score of 19/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Pulmonx Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Pulmonx Corporation scores 7.2 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

Models cluster within a tight range (+12.2% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LUNG valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across LUNG's 2 active models, average confidence is 45%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Pulmonx Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

10 related Medical Devices stocks with 13-model coverage

AORTArtivion, Inc.QOC 7.3IARTIntegra LifeSciences Holdings CorporationQOC 7.1SGHTSight Sciences, Inc.QOC 7.3PHGKoninklijke Philips N.V.QOC 7.1SRTSSensus Healthcare, Inc.QOC 7.3KIDSOrthoPediatrics Corp.QOC 7.1STIMNeuronetics, Inc.QOC 6.2CATXPerspective Therapeutics, Inc.QOC 5.2IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: AORT · IART · SGHT · PHG · SRTS · KIDS · STIM · CATX · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to LUNG?

7 companies across all industries closest to LUNG’s Quality of Company score of 7.2/10.

ROOTRoot, Inc.QOC 7.2ARTWArt's-Way Manufacturing Co., Inc.QOC 7.2MRDNMeridian Holdings Inc.QOC 7.2RECTRectitude Holdings LtdQOC 7.2GBFHGBank Financial Holdings Inc.QOC 7.2ALHCAlignment Healthcare, Inc.QOC 7.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ROOT · ARTW · MRDN · RECT · GBFH · ALHC · NVDA

Where Does LUNG Sit in CirclFi's Medical Devices Rankings?

LUNG is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Pulmonx Corporation’s Valuation?

What is Pulmonx Corporation's intrinsic value in 2026?

CirclFi puts Pulmonx Corporation (LUNG)'s intrinsic value at $1.64 — the median of 2 independent model estimates as of 2026-08-27, ranging from $1.49 to $1.79. The Quality of Company score is 7.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LUNG overvalued or undervalued right now?

At $2.42, 0 of 2 active models suggest LUNG may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $1.64, 32.3% below the current price of $2.42 — a consensus view that LUNG is overvalued. The assessment depends on which methodology best fits Pulmonx Corporation's business model in Medical Devices.

What does a Quality of Company score of 7.2 mean for LUNG?

Pulmonx Corporation's QOC of 7.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on LUNG?

CirclFi analyzes LUNG with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is LUNG a value trap in 2026?

Pulmonx Corporation's Value Trap score is 19/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Pulmonx Corporation (LUNG) has a median fair value of $1.64 — 32.3% below the current price of $2.42 — as of 2026-08-27.” Source: circlfi.com/stock/LUNG/ · Methodology
Primary sources for this LUNG valuation
  • Financial statements: Pulmonx Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001127537) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for LUNG as of ; valuations recomputed .